Expression of OATP family members in hormone-related cancers: Potential markers of progression

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Pressler, Heather ^a,b   Sissung, Tristan M ^a   Venzon, David ^a   Price, Douglas K ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER 1B3; ORGANIC ANION TRANSPORTER 2B1; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER TISSUE; COLON CANCER; CONTROLLED STUDY; GENE EXPRESSION; GLEASON SCORE; HORMONE RELATED CANCER; HUMAN; HUMAN TISSUE; LIVER CANCER; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; SLCO1B1 GENE; SLCO1B3 GENE; SLCO2B1 GENE; TESTIS CANCER; THYROID CANCER; TUMOR GENE; DISEASE COURSE; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY;

DISEASE PROGRESSION; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; ORGANIC ANION TRANSPORTERS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 79956268032     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020372     Document Type: Article

References (21)

1. Hamada A, Sissung T, Price DK, Danesi R, Chau CH, et al. (2008) Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 14: 3312-3318.
2. Lee W, Belkhiri A, Lockhart AC, Merchant N, Glaeser H, et al. (2008) Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res 68: 10315-10323.
3. Hagenbuch B GC, (2008) Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38: 778-801.
4. Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER,et al. Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol 44: 152-167.
5. Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, et al. (2008) A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int 102: 617-621.
6. Wright JL, Kwon EM, Ostrander EA, Montgomery B, Line DW, et al. (2011) Expression of SLCO transport genes in castration resistant prostate cancer and impact of genetic variation in SCLO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev.
7. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, et al. (2009) Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85: 155-163.
8. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A, (2005) Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 4: 815-818.
9. Vavricka SR, Jung D, Fried M, Grutzner U, Meier PJ, et al. (2004) The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J Hepatol 40: 212-218.
10. Ieiri I, Higuchi S, Sugiyama Y, (2009) Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 5: 703-729.
11. Justenhoven C, Schaeffeler E, Winter S, Baisch C, Hamann U, et al. (2010) Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with breast cancer risk. Breast Cancer Res Treat.
12. Imada S, Akaza H, Ami Y, Koiso K, Ideyama Y, et al. (1997) Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Eur Urol 31: 360-364.
13. Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, et al. (2007) Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 99: 558-568.
14. Ferlin A, Ganz F, Pengo M, Selice R, Frigo AC, et al. (2010) Association of testicular germ cell tumor with polymorphisms in estrogen receptor and steroid metabolism genes. Endocr Relat Cancer 17: 17-25.
15. Sherman ME, Madigan MP, Lacey JV Jr, Garcia-Closas M, Potischman N, et al. (2007) Ovarian volumes among women with endometrial carcinoma: associations with risk factors and serum hormones. Gynecol Oncol 107: 431-435.
16. Blechet C, Lecomte P, De Calan L, Beutter P, Guyetant S, (2007) Expression of sex steroid hormone receptors in C cell hyperplasia and medullary thyroid carcinoma. Virchows Arch 450: 433-439.
17. Giron RA, Montano LF, Escobar ML, Lopez-Marure R, (2009) Dehydroepiandrosterone inhibits the proliferation and induces the death of HPV-positive and HPV-negative cervical cancer cells through an androgen- and estrogen-receptor independent mechanism. FEBS J 276: 5598-5609.
18. Melvin WS, Boros LG, Muscarella P, Brandes JL, Johnson JA, et al. (1997) Dehydroepiandrosterone-sulfate inhibits pancreatic carcinoma cell proliferation in vitro and in vivo. Surgery 121: 392-397.
19. Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, et al. (2010) SLCO2B1 and SLCO1B3 may function as pharmacogenomic determinants of resistance to androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology submitted.
20. Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A, Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J ClinOncol 28: 4562-4567.
21. Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, et al. (2010) Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol 44: 152-167.